+

TN2009000167A1 - Crystalline potassium salt of lipoxin a4 analogs - Google Patents

Crystalline potassium salt of lipoxin a4 analogs

Info

Publication number
TN2009000167A1
TN2009000167A1 TNP2009000167A TN2009000167A TN2009000167A1 TN 2009000167 A1 TN2009000167 A1 TN 2009000167A1 TN P2009000167 A TNP2009000167 A TN P2009000167A TN 2009000167 A TN2009000167 A TN 2009000167A TN 2009000167 A1 TN2009000167 A1 TN 2009000167A1
Authority
TN
Tunisia
Prior art keywords
crystalline potassium
lipoxin
potassium salt
analogs
crystalline
Prior art date
Application number
TNP2009000167A
Other languages
English (en)
Inventor
Tilo Haag
Danja Grossbach
Gabriele Winter
Michael Sander
Wolfgang Beckmann
Klaus Bartel
Christian Dinter
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39076610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000167(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of TN2009000167A1 publication Critical patent/TN2009000167A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
TNP2009000167A 2006-12-04 2009-04-29 Crystalline potassium salt of lipoxin a4 analogs TN2009000167A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87283006P 2006-12-04 2006-12-04
PCT/EP2007/010785 WO2008068041A1 (fr) 2006-12-04 2007-12-04 Sel de potassium cristallin d'analogues de la lipoxine a4

Publications (1)

Publication Number Publication Date
TN2009000167A1 true TN2009000167A1 (en) 2010-10-18

Family

ID=39076610

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000167A TN2009000167A1 (en) 2006-12-04 2009-04-29 Crystalline potassium salt of lipoxin a4 analogs

Country Status (29)

Country Link
US (2) US7906678B2 (fr)
EP (2) EP2089350B1 (fr)
JP (1) JP5410984B2 (fr)
KR (3) KR20090101169A (fr)
CN (1) CN101553456B (fr)
AR (1) AR064116A1 (fr)
AU (1) AU2007327765B2 (fr)
BR (1) BRPI0719679A2 (fr)
CA (1) CA2670791C (fr)
CL (1) CL2007003468A1 (fr)
CO (1) CO6190608A2 (fr)
CR (1) CR10837A (fr)
DO (1) DOP2009000130A (fr)
EA (1) EA018615B1 (fr)
EC (1) ECSP099380A (fr)
HK (1) HK1135961A1 (fr)
IL (1) IL198434A (fr)
MA (1) MA31079B1 (fr)
MX (1) MX2009005911A (fr)
MY (1) MY147951A (fr)
NO (1) NO20092528L (fr)
NZ (1) NZ577338A (fr)
PE (2) PE20120395A1 (fr)
SV (1) SV2009003286A (fr)
TN (1) TN2009000167A1 (fr)
TW (1) TWI415833B (fr)
UY (1) UY30755A1 (fr)
WO (1) WO2008068041A1 (fr)
ZA (1) ZA200904689B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120395A1 (es) * 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4
US20090036530A1 (en) * 2006-12-04 2009-02-05 Bayer Schering Pharma Aktiengesellschaft Crystalline acid of lipoxin A4 analogs and method of making
EP2135610A1 (fr) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combinaison comportant des inhibiteurs DHODH et de la méthotrexate
AU2010286681A1 (en) * 2009-08-27 2012-02-09 Merck Sharp & Dohme Corp. Processes for preparing protease inhibitors of hepatitis C virus
EP2958560B1 (fr) * 2013-02-21 2019-05-08 Forsyth Dental Infirmary for Children Méthodes permettant d'augmenter l'ostéogenèse de la cavité buccale au moyen de la lipoxine a4 (lxa4) et de ses analogues
WO2016149582A1 (fr) * 2015-03-18 2016-09-22 The Forsyth Institute Procédés pour stabiliser des plaques d'athérosclérose à l'aide de lipoxines, de résolvines et de leurs analogues
CN109562186B (zh) 2016-06-03 2022-09-13 西蒂斯制药有限责任公司 与专门促消退介质的盐有关的组合物和方法
CN110709138A (zh) 2017-01-31 2020-01-17 布里格姆及妇女医院股份有限公司 Alx受体配体定义炎症性疾病的生化内型
CN111875530A (zh) * 2020-08-17 2020-11-03 浙江朗华制药有限公司 一种普拉西坦水合物晶体及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
ES2313715T3 (es) 1993-06-15 2009-03-01 The Brigham And Women's Hospital, Inc. Compuestos de lipoxina con semivida prolongada.
AU7215294A (en) 1993-06-29 1995-01-24 Brigham And Women's Hospital Modulation of inflammation related to columnar epithelia
US6008205A (en) 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
US6236978B1 (en) * 1997-11-14 2001-05-22 New York University System and method for dynamic profiling of users in one-to-one applications
US6006466A (en) * 1998-08-20 1999-12-28 Washecka; John Concealed linear payout holder for fishing leader
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
DE60022327T2 (de) 1999-03-18 2006-06-29 The Brigham And Women's Hospital Inc., Boston Lipoxinverbindungen und ihre anwendung
AU780114B2 (en) 1999-03-18 2005-03-03 Brigham And Women's Hospital Regulation of phospholipase D activity
AU775140B2 (en) 1999-03-18 2004-07-22 Brigham And Women's Hospital Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response
DK1237549T3 (da) 1999-11-09 2004-06-07 Alcon Inc Lipoxin A4 og dets analoger til behandling af törre öjne
AU2001249329A1 (en) 2000-03-20 2001-10-03 Brigham And Women's Hospital Lipoxin analogs and methods for the treatment of periodontal disease
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
CN1617875A (zh) 2001-12-13 2005-05-18 兰贝克赛实验室有限公司 结晶二水合头孢地尼钾
JP4634716B2 (ja) 2002-03-15 2011-02-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ５−［４−［［３−メチル−４−オキソ−３，４−ジヒドロキナゾリン−２−イル］メトキシ］ベンジル］チアゾリジン−２，４−ジオンカリウム塩の新規な結晶形
EP1589966B1 (fr) 2003-01-30 2010-11-10 LEK Pharmaceuticals d.d. Preparation de nouveaux sels pharmaceutiquement acceptables du losartan et des variantes correspondantes, et nouveaux procedes permettant de purifier et d'isoler ces sels
WO2006035291A1 (fr) 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Formes cristallines de cefdinir potassium
US7223718B2 (en) * 2005-03-07 2007-05-29 Falcon Lab Llc Enhanced glyphosate herbicidal concentrates
KR20070088764A (ko) 2005-10-31 2007-08-29 테바 파마슈티컬 인더스트리즈 리미티드 세프디니어 칼륨염의 결정형
PE20120395A1 (es) * 2006-12-04 2012-05-23 Bayer Ip Gmbh Sal de potasio cristalina de analogos de lipoxina a4

Also Published As

Publication number Publication date
MX2009005911A (es) 2009-09-07
AU2007327765A1 (en) 2008-06-12
AR064116A1 (es) 2009-03-11
MY147951A (en) 2013-02-15
ECSP099380A (es) 2009-11-30
EP2089350B1 (fr) 2018-08-22
BRPI0719679A2 (pt) 2014-01-14
CN101553456A (zh) 2009-10-07
CR10837A (es) 2009-07-23
IL198434A (en) 2012-09-24
IL198434A0 (en) 2010-02-17
NO20092528L (no) 2009-08-26
US20080182897A1 (en) 2008-07-31
MA31079B1 (fr) 2010-01-04
KR20090101169A (ko) 2009-09-24
EP3489214A1 (fr) 2019-05-29
JP2010511649A (ja) 2010-04-15
ZA200904689B (en) 2011-10-26
TWI415833B (zh) 2013-11-21
CN101553456B (zh) 2013-08-28
UY30755A1 (es) 2008-07-31
PE20120395A1 (es) 2012-05-23
CA2670791A1 (fr) 2008-06-12
CL2007003468A1 (es) 2008-07-04
KR20160054030A (ko) 2016-05-13
US8049035B2 (en) 2011-11-01
TW200838847A (en) 2008-10-01
US20110124910A1 (en) 2011-05-26
JP5410984B2 (ja) 2014-02-05
CO6190608A2 (es) 2010-08-19
EA018615B1 (ru) 2013-09-30
EA200900732A1 (ru) 2009-12-30
NZ577338A (en) 2011-02-25
AU2007327765B2 (en) 2012-04-12
WO2008068041A1 (fr) 2008-06-12
KR20140135847A (ko) 2014-11-26
PE20081200A1 (es) 2008-11-06
US7906678B2 (en) 2011-03-15
SV2009003286A (es) 2009-10-02
HK1135961A1 (en) 2010-06-18
EP2089350A1 (fr) 2009-08-19
DOP2009000130A (es) 2009-08-15
CA2670791C (fr) 2017-01-03

Similar Documents

Publication Publication Date Title
TN2009000167A1 (en) Crystalline potassium salt of lipoxin a4 analogs
PH12017501426A1 (en) Derivatives of betulin
TN2011000400A1 (en) Inhibitors of beta-secretase
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
PH12013501704A1 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
UA105229C2 (uk) Фармацевтичний склад
MX2011011776A (es) Nuevos profarmacos de triptolite.
TN2012000248A1 (en) Novel spiropiperidine compounds
MX348228B (es) Cristal de derivados de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo.
PH12012502216A1 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt
MX2013011257A (es) Proceso para la preparacion de dronedarona por n-butilacion.
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
MX2011011733A (es) Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos.
IN2014MN01521A (fr)
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
IN2012DN02502A (fr)
IN2014CN04449A (fr)
WO2013177534A3 (fr) Nouveaux dérivés d'acide salicylique, sel de qualité pharmaceutique correspondant, composition et procédé d'utilisation correspondants
MX2011009898A (es) Proceso para la obtencion de derivados de acido propionico.
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
EA201270302A1 (ru) Безводные формы производных пиридина
WO2010132670A3 (fr) Composés pentacyclines
MX343165B (es) Agonistas del receptor 5-ht4 para el tratamiento de demencia.
IN2014MN00971A (fr)
MX2012007426A (es) Derivados de amino-heteroarilo como bloqueadores de los canales activados por la hiperpolarizacion, controlados por nucleotidos ciclicos.
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载